Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Moderna (MRNA) traded higher in the premarket on Thursday after the Cambridge, Massachusetts-based biotech exceeded Street ...
Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...
CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is ...
CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback